PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Body Protection Compound-157, PL 14736
Body Protective CompoundLast Updated: April 1, 2026
BPC-157 (also known as Body Protection Compound-157, PL 14736) is a prominently researched experimental compound classified strictly within the Body Protective Compound framework. Operating primarily through advanced pharmacological pathways, it functions by promotes angiogenesis, collagen deposition, and modulates growth factors for accelerated healing. Acts on multiple repair pathways simultaneously including tendon, ligament, muscle, gut lining, and nerve tissue. with a documented biological half-life of roughly 4 hours, in preclinical investigative trials and independent academic studies, researchers utilizing BPC-157 have documented significant, quantifiable biological outcomes, primarily focusing on injury recovery, gut healing, tissue repair, reduced inflammation. Typical research protocols investigate administering 500 to 500mcg via subq pathways 7x/wk. However, it is critically important to understand that while BPC-157 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
Promotes angiogenesis, collagen deposition, and modulates growth factors for accelerated healing. Acts on multiple repair pathways simultaneously including tendon, ligament, muscle, gut lining, and nerve tissue.
Comprehensive review demonstrating potent tendon, ligament, and gut healing effects across multiple preclinical models.
preclinicalRobert et al. demonstrate BPC-157 heals GI ulcers, fistulas, and inflammatory bowel lesions in rats via cytoprotective pathways. Published in Current Pharmaceutical Design.
preclinicalStaresinic et al. show BPC-157 accelerates healing of transected Achilles tendons, enhancing tendon fibroblast outgrowth and survival via FAK-paxillin signaling.
preclinicalSystematic review of 35 preclinical and 1 clinical study (1993-2024). BPC-157 promotes angiogenesis, collagen synthesis, and reduces inflammatory cytokines across muscle, tendon, ligament, and bone injury models.
preclinicalPreclinical evidence showing BPC-157 counteracts stroke-induced neuronal damage and improves functional recovery after spinal cord compression in rats.
preclinicalDemonstrates BPC-157's strong angiogenic potential via VEGFR2-Akt-eNOS pathway activation, endothelium protection, and reversal of thrombus formation.
preclinicalExcellent research safety profile; commonly used for recovery. Not FDA-approved. Most evidence from animal models. FDA restricted use in compounded medications in Sept 2023.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Often run 250mcg 2x/day for injuries. Can be injected near injury site.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
Reduced pain/inflammation at injury site; improved GI comfort if used for gut healing
Weeks 2-4
Noticeable mobility improvement; significant reduction in injury-site swelling
Month 2-3
Substantial tissue remodeling; most acute injuries showing measurable repair
Long-term
Full tendon/ligament functional recovery in most preclinical models; sustained GI remission
| Side Effect | Incidence | Severity |
|---|---|---|
Lightheadedness | ~5% of users | mild |
Nausea (especially oral route) | ~3-5% of users | mild |
Vivid dreams | ~5% of users | mild |
Euphoria / mood lift Often not considered adverse; may reflect CNS activity | ~8% of users | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Finding verified, high-purity BPC-157 requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified BPC-157✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
A deep dive into peptide stacking protocols — the Wolverine stack (BPC-157 & TB-500), growth hormone synergy (CJC-1295 & Ipamorelin), longevity and cognitive stacks, and how to combine compounds effectively.
A comprehensive analysis of the 2026 FDA peptide reclassification — which 14 peptides are returning to Category 1, what it means for patients and providers, and how to navigate peptide therapy safely.
A research-backed safety analysis of popular peptides including BPC-157, semaglutide, and GHK-Cu — covering clinical safety data, purity risks, and side effect profiles.
A research-backed guide to peptide stacking — principles of safe combination, popular stacks for recovery, body composition, and longevity, timing, and contraindications.
PeptiDex. (2026). BPC-157. PeptiDex Research Platform. https://peptidex.app/library/bpc-157
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.